Market news

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.

Price targets on Karyopharm Therapeutics have swung sharply, with one bullish firm trimming its view from US$14 to US$11 and a more cautious house cutting from US$15 to US$3. These shifts reflect the split in analyst commentary, which now hinges on how investors weigh the myelofibrosis opportunity against the endometrial cancer setback and recent stock volatility. Read on to see how to follow this evolving narrative and what to watch as new data and regulatory decisions come through. Stay...

On August 13, Karyopharm Therapeutics (NASDAQ:KPTI) held its second-quarter earnings call, and the story split cleanly in two. The company laid out a myelofibrosis combination therapy with data strong enough to earn an accelerated approval pathway from the FDA, alongside a cash position that funds operations only into September. A $15.8 million loan payment lands […]

Detailed price information for Karyopharm Therapeut (KPTI-Q) from The Globe and Mail including charting and trades.

Moby summary of Karyopharm Therapeutics Inc.'s Q2 2026 earnings call

Karyopharm reports promising myelofibrosis data and plans for accelerated approval sNDA, while navigating a tight cash position and failed endometrial cancer program.

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics: Q2 Earnings Snapshot

Detailed price information for Teladoc Health Inc (TDOC-N) from The Globe and Mail including charting and trades.

Karyopharm Therapeutics (KPTI) has an average rating of overweight and mean price target of $9.83, a

The global, randomised, double-blind, placebo-controlled trial enrolled 257 adults.

Karyopharm stock plunged after hours after its Phase 3 endometrial cancer trial missed the primary endpoint.

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal.

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Tipranks Press Release.